Amylyx Pharmaceuticals (AMLX) Other Non Operating Income (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) recorded quarterly Other Non Operating Income of -$75000.0 in Q1 2026, down 120.72% quarter-over-quarter from $362000.0 in Q4 2025, and up 77.61% on a YoY basis from -$42226.9 in Q1 2025.
Amylyx Pharmaceuticals (AMLX) Other Non Operating Income (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Other Non Operating Income history runs 6 years deep, the most recent figure standing at -$75000.0 for Q1 2026.
- In Q1 2026, Other Non Operating Income rose 77.61% year-over-year to -$75000.0; the TTM figure through Mar 2026 stood at -$439000.0 (up 45.26% YoY), while the FY2025 annual figure was -$700000.0, up 42.34% from the prior year.
- Other Non Operating Income was -$75000.0 for Q1 2026 at Amylyx Pharmaceuticals, down from $362000.0 in the prior quarter.
- In the past five years, Other Non Operating Income ranged from a high of $362000.0 in Q4 2025 to a low of -$747000.0 in Q1 2024.
- Historically, Other Non Operating Income has averaged -$188176.5 across 5 years, with a median of -$141000.0 in 2024.
- The sharpest annual moves came in 2022 and 2023: Other Non Operating Income jumped 187.67% in 2022, then tumbled 1278.95% in 2023.
- A 5-year view of Other Non Operating Income shows it stood at -$689000.0 in 2022, then jumped by 124.82% to $171000.0 in 2023, then fell by 8.19% to $157000.0 in 2024, then surged by 130.57% to $362000.0 in 2025, then tumbled by 120.72% to -$75000.0 in 2026.
- The last three Other Non Operating Income figures came in at -$75000.0 (Q1 2026), $362000.0 (Q4 2025), and -$180000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.97 Bn | 36.23 Bn | 1.97 Bn |
| 2 | Zoetis | 33.59 Bn | 31.65 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn |
| 4 | Neurocrine Biosciences | 16.10 Bn | 14.78 Bn | 800.70 Mn |
| 5 | Aurora Cannabis | 15.56 Bn | 15.47 Bn | 21.72 Mn |
| 6 | Elanco Animal Health | 12.04 Bn | 11.61 Bn | 785.00 Mn |
| 7 | Alkermes | 7.36 Bn | 6.84 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.74 Bn | 6.24 Bn | 230.92 Mn |
| 9 | Liquidia | 6.27 Bn | 6.04 Bn | 121.79 Mn |
| 10 | Amylyx Pharmaceuticals | 1.61 Bn | 1.61 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -75,000.00 |
| Dec 31, 2025 | 362,000.00 |
| Sep 30, 2025 | -180,000.00 |
| Jun 30, 2025 | -546,000.00 |
| Mar 31, 2025 | -335,000.00 |
| Dec 31, 2024 | 157,000.00 |
| Sep 30, 2024 | -141,000.00 |
| Jun 30, 2024 | -483,000.00 |
| Mar 31, 2024 | -747,000.00 |
| Dec 31, 2023 | 171,000.00 |
| Sep 30, 2023 | -488,000.00 |
| Jun 30, 2023 | -81,000.00 |
| Mar 31, 2023 | -262,000.00 |
| Dec 31, 2022 | -689,000.00 |
| Sep 30, 2022 | 199,000.00 |
| Jun 30, 2022 | -42,000.00 |
| Mar 31, 2022 | -19,000.00 |
| Dec 31, 2021 | -59,000.00 |
| Sep 30, 2021 | -227,000.00 |
| Jun 30, 2021 | -26,000.00 |